Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.
Back
Updates from IKCS 2023 and Surrounding Meetings in Advanced RCC
Brian Rini, MD, and Hans Hammers, MD, explore key data updates in the management of advanced renal cell carcinoma (RCC) presented at the 2023 IKCS: North America Congress and other recent meetings.
Updates from IKCS 2023 and Surrounding Meetings in Advanced RCC
Episodes
All
All
Experts highlight key clinical updates from the CLEAR trial presented at the 2023 IKCS: North America congress, assessing lenvatinib plus pembrolizumab in patients with advanced RCC.
A comprehensive discussion on toxicity management and patient tolerability for combination regimens in the setting of advanced RCC.
Brian Rini, MD, discusses the impact of real-world outcomes on treatment selection, highlighting frontline combination axitinib plus pembrolizumab in advanced RCC.
Drs Rini and Hammers discuss additional clinical readouts from the 2023 IKCS: North America meeting including emerging agents for advanced RCC such as belzutifan and zanzalitinib.
Experts close the discussion by sharing insights on the future in advanced RCC, emphasizing the development of emerging agents and combination regimens for the treatment landscape.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5